With global sales of $6.9bn in the first quarter of 2024, Merck & Co., Inc.’s anti-PD-1 cancer immunotherapy Keytruda (pembrolizumab) retained its title as the best-selling drug, a position it has held every quarter since the start of 2023.
Although its quarterly total falls a long way short of the highest single-quarter revenues ever reported for a drug, Keytruda...








